Charles River director exercises options, sells shares

Q: What insider transaction did CRL director James C. Foster report on August 10, 2026?

James C. Foster reported exercising stock options for 28,733 shares of Charles River Laboratories common stock at $179.66 per share and selling 28,733 shares at $275.00 per share, all on August 10, 2026, as disclosed in the Form 4.

Q: Was the August 10, 2026 CRL insider sale by James C. Foster under a Rule 10b5-1 plan?

Yes. The exercise and sale of 28,733 CRL shares by James C. Foster occurred under a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026, indicating the trades were pre-arranged rather than discretionary.

Q: What stock option terms applied to James C. Foster’s CRL option exercise reported in this Form 4?

Foster exercised stock options covering 28,733 shares of Charles River Laboratories common stock at an exercise price of $179.66 per share. The option grant became exercisable on May 29, 2021 and carried an expiration date of May 29, 2030 before this full exercise.

Q: At what price did James C. Foster sell CRL common stock on August 10, 2026?

He sold 28,733 shares of Charles River Laboratories common stock at a reported price of $275.00 per share on August 10, 2026. The transaction is coded as a sale (code S) in the Form 4’s non-derivative transaction table.

Q: How many CRL stock options remained from the exercised grant after James C. Foster’s transaction?

From this particular option grant, the Form 4 reports 0 derivative shares remaining following the August 10, 2026 exercise of 28,733 options, indicating that this specific grant of stock options was fully exercised in the reported transaction.

Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share. The options, originally exercisable from May 29, 2021 and expiring May 29, 2030, now show 0 derivative shares remaining from this grant. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster is reported with indirect holdings of common stock through various trusts and GRATs, including 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, and 20,000 shares in a 2026 GRAT.

Insider Trade Summary 10b5-1

Exercise and Sale: 28,733 shares ($2.74M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider FOSTER JAMES C

Role Director

Sold 28,733 shs ($7.90M)

Approx. gross sale proceeds $7.90M

Approx. exercise cost $5.16M

Approx. pre-tax spread $2.74M

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	28,733	$0.00	$0.00
Exercise	Common Stock	28,733	$179.66	$5.16M
Sale	Common Stock ^F1	28,733	$275.00	$7.90M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 0 contracts (Direct); Common Stock — 31,596 shares (Direct); Common Stock — 5,423 shares (Indirect, 2024 GRAT); Common Stock — 10,780 shares (Indirect, 2025 GRAT); Common Stock — 20,000 shares (Indirect, 2026 GRAT); Common Stock — 155,611 shares (Indirect, By Trust); Common Stock — 10,000 shares (Indirect, By Trust Held By Spouse)

Footnotes (1)

F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.

Key Figures

Options Exercised: 28,733 shares Exercise Price: $179.66 per share Sale Price: $275.00 per share +4 more

7 metrics

Options Exercised 28,733 shares Stock options (right to buy) exercised on August 10, 2026

Exercise Price $179.66 per share Exercise price of stock options converted into common stock

Sale Price $275.00 per share Price for sale of 28,733 common shares on August 10, 2026

Shares Sold 28,733 shares Common stock sold in non-derivative transaction coded S

2024 GRAT Holdings 5,423 shares Indirect common stock holdings through 2024 GRAT after transactions

2025 GRAT Holdings 10,780 shares Indirect common stock holdings through 2025 GRAT after transactions

2026 GRAT Holdings 20,000 shares Indirect common stock holdings through 2026 GRAT after transactions

Key Terms

Rule 10b5-1 Trading Plan, Stock Options (Right to Buy), derivative security, GRAT, +1 more

5 terms

Rule 10b5-1 Trading Plan regulatory

"This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

GRAT financial

"nature_of_ownership: 2024 GRAT"

By Trust Held By Spouse financial

"nature_of_ownership: By Trust Held By Spouse"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRL director James C. Foster report on August 10, 2026?

James C. Foster reported exercising stock options for 28,733 shares of Charles River Laboratories common stock at $179.66 per share and selling 28,733 shares at $275.00 per share, all on August 10, 2026, as disclosed in the Form 4.

Was the August 10, 2026 CRL insider sale by James C. Foster under a Rule 10b5-1 plan?

Yes. The exercise and sale of 28,733 CRL shares by James C. Foster occurred under a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026, indicating the trades were pre-arranged rather than discretionary.

What stock option terms applied to James C. Foster’s CRL option exercise reported in this Form 4?

Foster exercised stock options covering 28,733 shares of Charles River Laboratories common stock at an exercise price of $179.66 per share. The option grant became exercisable on May 29, 2021 and carried an expiration date of May 29, 2030 before this full exercise.

At what price did James C. Foster sell CRL common stock on August 10, 2026?

He sold 28,733 shares of Charles River Laboratories common stock at a reported price of $275.00 per share on August 10, 2026. The transaction is coded as a sale (code S) in the Form 4’s non-derivative transaction table.

Does James C. Foster still hold CRL shares indirectly after the reported Form 4 transactions?

Yes. After the August 10, 2026 transactions, indirect holdings reported include 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, 20,000 shares in a 2026 GRAT, plus additional shares held by other trusts associated with Foster and his spouse.

How many CRL stock options remained from the exercised grant after James C. Foster’s transaction?

From this particular option grant, the Form 4 reports 0 derivative shares remaining following the August 10, 2026 exercise of 28,733 options, indicating that this specific grant of stock options was fully exercised in the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/11/2026 - 04:35 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOSTER JAMES C

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		M		28,733	A	$179.66	60,329	D
Common Stock	08/10/2026		S		28,733⁽¹⁾	D	$275	31,596	D
Common Stock								5,423	I	2024 GRAT
Common Stock								10,780	I	2025 GRAT
Common Stock								20,000	I	2026 GRAT
Common Stock								155,611	I	By Trust
Common Stock								10,000	I	By Trust Held By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$179.66	08/10/2026		M			28,733	05/29/2021	05/29/2030	Common Stock	28,733	$0	0	D

Explanation of Responses:

1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.

	/s/ James C. Foster	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR